Journal article
Azacitidine and its role in the upfront treatment of acute myeloid leukemia
Abstract
INTRODUCTION: Acute myeloid leukemia (AML) predominantly affects elderly population. This poses challenges in management, as patients are frequently not candidates for intensive therapy given comorbidities or frailty. Currently, azacitidine (AZA), either as monotherapy or in combination regimens, is the backbone treatment in this group of patients.
AREAS COVERED: We review the mechanism of action, pharmacology, clinical efficacy, and safety of …
Authors
Raslan O; Garcia-Horton A
Journal
Expert Opinion on Pharmacotherapy, Vol. 23, No. 8, pp. 873–884
Publisher
Taylor & Francis
Publication Date
May 24, 2022
DOI
10.1080/14656566.2022.2082284
ISSN
1465-6566